Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers

Date

08 Oct 2016

Session

Basic science and translational research

Presenters

Janessa Laskin

Citation

Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392

Authors

J. Laskin1, C. Ho1, Y. Shen2, M. Jones2, K.A. Gelmon1, H. Lim1, D.J. Renouf1, S. Yip3, A. Tinker1, K. Khoo4, C. Lohrisch1, S. Chia1, B. Deol1, K. Schrader5, Y. Ma2, R. Moore2, A. Mungall2, S. Jones2, M. Marra2

Author affiliations

  • 1 Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 2 Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver/CA
  • 3 Pathology, BC Cancer Agency, Vancouver General Hospital University of British Columbia, Vancouver/CA
  • 4 Medical Oncology, BC Cancer Agency, Kelowna/CA
  • 5 Hereditary Cancer Program, British Columbia Cancer Agency, Vancouver/CA
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2657

Background

Whole genome analyses have the potential to identify the full landscape of genomic abnormalities within cancers, and can therefore be used to provide rationales for cancer treatments. The Personalized OncoGenomics study integrates DNA and RNA sequencing information into oncology practice; this analysis evaluates how physicians use the data for clinical decisions and the role of RNA data in identifying actionable targets.

Methods

Pts with advanced tumors and a survival > 6 m were eligible. Each had a tumour biopsy and blood sample which underwent comprehensive DNA (80X) and RNA sequencing followed by bioinformatic analysis including assembly, annotation, and mining of the data to identify somatic aberrations, gene expression changes or other putative cancer “drivers” or actionable targets. Gene expression from tumour RNAseq was compared to the TCGA and Illumina body map. Results were discussed in a multidisciplinary Clinical Genomics Tumour board and characterized as informative, actionable or neither. Clinical actionability can be based on abnormalities of DNA, RNA or both.

Results

Between July 2012 and April 2016, 217 pts had complete sequencing data available. Of these, 165 pts had clinically actionable, and 52 had no actionable pathways identified. Of the165 actionable patients: 34 pending progression, 60 received no POG directed therapy and 71 had POG informed treatment. 60 with no POG directed therapy: 24 poor PS/deceased, 16 clinical trial or off-label treatment not available, 20 POG data was not utilized. 71 treated using POG data: 13 clinical trial, 29 off label treatment and 29 treatment within guidelines of disease site. 40% of the treatment decisions were based on the RNA information; 45% on a combination of DNA and RNA; and 15% based on DNA alone.

Conclusions

Data from DNA abnormalities alone corresponds to the rate noted in panel associated drug matching trials. The availability of RNA expression information greatly increased our ability to identify clinically actionable targets. With the support of the multidisciplinary tumour board meetings and a tiered data system, oncologists had sufficient confidence in the results to seek clinical trials and off-label therapies based on genomic data in the majority of pts.

Clinical trial identification

NCT02155621

Legal entity responsible for the study

BC Cancer Agency

Funding

BC Cancer Foundation

Disclosure

J. Laskin: Academic talk honoraria: Az, Roche, BI Research funds to institution: Lilly, BI. C. Ho: Honoraria AZ, Bayer, BMS, BI, Pfizer, Lilly, Roche Research grants BI, Genzyme. Travel grant BI. H. Lim: Honoraria/Consulting/Research Funding: Eli Lilly, Leo, Bayer, Ipsen, Amgen. D.J. Renouf: Honoraria – Celgene. S. Chia: Personal honorarium Hoffmann LaRoche, Novartis, Genomic Health and Amgen. My institution has received funding for clinical trials from Hoffmann LaRoche, Novartis, Genomic Health, AstraZeneca, Genetech, and Amgen. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings